ArticleHeart (British Cardiac Society)2020
Prognostic value of C-reactive protein in adults with congenital heart disease.
Article in Heart (British Cardiac Society), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Role of Chronic Inflammation in Polycystic Ovarian Syndrome-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2021Pooled it
- Associations of Overweight and Obesity Indicators with Cardiometabolic Risk Profile in Children and Adolescents with Congenital Heart Disease.Pediatric cardiology · 2026Article
- Cardiorenal Biomarkers and Cerebrovascular Risk in Patients with Congenital Heart Disease.Journal of clinical medicine · 2026Article
- Epigenetic age acceleration in young adults with congenital heart disease.Clinical epigenetics · 2026Article
- Role of MMP-2, MMP-9, TIMP-1, and TIMP-2 in children with ventricular septal defect.Biomolecules & biomedicine · 2025Article
- Blood Biomarkers Predict 10-Year Clinical Outcomes in Adult Patients With Congenital Heart Disease.JACC. Advances · 2024Article
- Subpulmonary ventricular function and inflammation are related to clinical heart failure in patients with a systemic right ventricle.International journal of cardiology. Congenital heart disease · 2024Article
- A complex case of univentricular heart with multiple congenital malformations diagnosed in a newborn: a case report and literature review.Annals of medicine and surgery (2012) · 2024Article
- C-Reactive Protein and Long-Term Prognosis in Adult Patients with Congenital Heart Disease.Journal of clinical medicine · 2024Article
- Assessment of the Relationship between Periodontitis and Cardiac Parameters in Patients with Early Chronic Heart Failure: A Cross-Sectional Study.Journal of functional morphology and kinesiology · 2024Article
- Inflammation in Heart Failure-Future Perspectives.Journal of clinical medicine · 2023Review
- Biological Age in Congenital Heart Disease-Exploring the Ticking Clock.Journal of cardiovascular development and disease · 2023Review
- NT-proBNP Is a Predictor of Mortality in Adults with Pulmonary Arterial Hypertension Associated with Congenital Heart Disease.Journal of clinical medicine · 2023Article
- Born to Age: When Adult Congenital Heart Disease Converges With Geroscience.JACC. Advances · 2022Review
- Serial cardiac biomarker assessment in adults with congenital heart disease hospitalized for decompensated heart failureInternational journal of cardiology. Congenital heart disease · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-sensitivity C reactive protein (hs-CRP) has been associated with outcomes in adult congenital heart disease (ACHD). However, its prognostic value beyond N-terminal pro B type natriuretic peptide (NT-proBNP) or troponin T remains unknown. We studied the temporal evolution of hs-CRP, as well as the relation between hs-CRP and adverse clinical outcomes independent of NT-proBNP and troponin T in patients with ACHD.
methodsIn this prospective cohort study, we enrolled 602 patients with ACHD (2011-2013) who underwent baseline and thereafter annual blood sampling during 4 years. Hs-CRP, hs-troponin T and NT-proBNP were measured. The primary endpoint was composed of death or heart failure (HF). Cox regression and Joint Modelling was used to relate 2log hs-CRP levels with the endpoint, with adjustment for baseline characteristics and (repeated) hs-troponin T and NT-proBNP measurements.
resultsHs-CRP was measured at baseline in 591 patients, median age 33 years, 58% men, 90% New York Heart Association I with an average of 4.3 measurements per patient. Median follow-up was 5.9 (IQR 5.3-6.3) years (99.2% complete) and 69 patients met the endpoint. Higher baseline hs-CRP was independently associated with higher risk of death or HF (HR 1.36, 95% CI 1.19 to 1.55). Hs-CRP increased over time prior to death or HF, and repeated hs-CRP measurements were associated with the endpoint, independent of repeated NT-proBNP and hs-troponin T (HR 1.54, 95% CI 1.24 to 1.98).
conclusionsHs-CRP carries incremental prognostic value for the risk of death or HF, beyond NT-proBNP and hs-troponin T. Hs-CRP increased prior to the occurrence of HF or death, supporting the role of inflammation in the clinical deterioration of patients with ACHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.